<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129820">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01411995</url>
  </required_header>
  <id_info>
    <org_study_id>201105067</org_study_id>
    <nct_id>NCT01411995</nct_id>
  </id_info>
  <brief_title>Cervical Lidocaine for Intrauterine Device Insertion Pain</brief_title>
  <acronym>CLIIP</acronym>
  <official_title>RCT of Cervical Lidocaine for Intrauterine Device Insertion Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate intracervical lidocaine gel as a means to decrease pain
      associated with intrauterine device (IUD) insertion. They will be randomized to either
      placebo (inert water based lubricating gel) or 2% lidocaine gel to be placed intracervically
      via angio-catheter just before IUD insertion. Anticipated pain scores will be assessed using
      a visual analog scale prior to insertion. Using the same pain scale, patients will again be
      asked at the end of the procedure to rate their pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>Immediately following insertion</time_frame>
    <description>Using a visual analog scale, women will report their level of pain pre-procedure, after tenaculum placement, and post-procedure.The entirety of teh procedure should last no more than 5-10 minuites. The pain score is assessed at the 3 timepoints within that 10 minuite window. No additional followup is required.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Pain</condition>
  <condition>Intrauterine Device</condition>
  <arm_group>
    <arm_group_label>2% Lidocaine gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women randomized to the Lidocaine arm will receive a total of 3-5cc of 2% gel at the tenaculum site and within the endocervical canal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Water based lubricant</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Women randomized to the placebo arm will receive a total of 3-5cc of water based lubricant at the tenaculum site and within the the endocervical canal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% lidocaine gel</intervention_name>
    <description>3-5cc of 2% lidocaine gel will be applied to the lip of the cervix and within the endocervical canal prior to IUD insertion</description>
    <arm_group_label>2% Lidocaine gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Water based lubricant</intervention_name>
    <description>3-5cc of water based lubricant will be applied to the lip of the cervix and within the endocervical canal prior to IUD insertion</description>
    <arm_group_label>Water based lubricant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-45 yrs

          -  selecting intrauterine device contraception

          -  able and willing to consent

        Exclusion Criteria:

          -  non-English speaking

          -  current intrauterine device use

          -  expulsion of intrauterine device within 2 weeks

          -  allergy to lidocaine or water based lubricant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Clinical Research at Washington University</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006 Jun;38(2):90-6.</citation>
    <PMID>16772190</PMID>
  </reference>
  <reference>
    <citation>Kulier R, O'Brien PA, Helmerhorst FM, Usher-Patel M, D'Arcangues C. Copper containing, framed intra-uterine devices for contraception. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005347. Review.</citation>
    <PMID>17943851</PMID>
  </reference>
  <reference>
    <citation>Rivera R, Best K. Current opinion: consensus statement on intrauterine contraception. Contraception. 2002 Jun;65(6):385-8. Review.</citation>
    <PMID>12127634</PMID>
  </reference>
  <reference>
    <citation>O'Brien PA, Kulier R, Helmerhorst FM, Usher-Patel M, d'Arcangues C. Copper-containing, framed intrauterine devices for contraception: a systematic review of randomized controlled trials. Contraception. 2008 May;77(5):318-27. doi: 10.1016/j.contraception.2007.12.011. Epub 2008 Mar 18. Review.</citation>
    <PMID>18402846</PMID>
  </reference>
  <reference>
    <citation>Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, Secura G. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011 May;117(5):1105-13. doi: 10.1097/AOG.0b013e31821188ad.</citation>
    <PMID>21508749</PMID>
  </reference>
  <reference>
    <citation>Massey SE, Varady JC, Henzl MR. Pain relief with naproxen following insertion of an intrauterine device. J Reprod Med. 1974 Dec;13(6):226-31.</citation>
    <PMID>4612152</PMID>
  </reference>
  <reference>
    <citation>Madden T, Allsworth JE, Hladky KJ, Secura GM, Peipert JF. Intrauterine contraception in Saint Louis: a survey of obstetrician and gynecologists' knowledge and attitudes. Contraception. 2010 Feb;81(2):112-6. doi: 10.1016/j.contraception.2009.08.002. Epub 2009 Sep 16.</citation>
    <PMID>20103447</PMID>
  </reference>
  <reference>
    <citation>Buttram V, Izu A, Henzl MR. Naproxen sodium in uterine pain following intrauterine contraceptive device insertion. Am J Obstet Gynecol. 1979 Jul 1;134(5):575-8.</citation>
    <PMID>453298</PMID>
  </reference>
  <reference>
    <citation>Hubacher D, Reyes V, Lillo S, Zepeda A, Chen PL, Croxatto H. Pain from copper intrauterine device insertion: randomized trial of prophylactic ibuprofen. Am J Obstet Gynecol. 2006 Nov;195(5):1272-7.</citation>
    <PMID>17074548</PMID>
  </reference>
  <reference>
    <citation>Dijkhuizen K, Dekkers OM, Holleboom CA, de Groot CJ, Hellebrekers BW, van Roosmalen GJ, Janssen CA, Helmerhorst FM. Vaginal misoprostol prior to insertion of an intrauterine device: an RCT. Hum Reprod. 2011 Feb;26(2):323-9. doi: 10.1093/humrep/deq348. Epub 2010 Dec 15.</citation>
    <PMID>21159683</PMID>
  </reference>
  <reference>
    <citation>Li YT, Kuo TC, Kuan LC, Chu YC. Cervical softening with vaginal misoprostol before intrauterine device insertion. Int J Gynaecol Obstet. 2005 Apr;89(1):67-8.</citation>
    <PMID>15777909</PMID>
  </reference>
  <reference>
    <citation>Sääv I, Aronsson A, Marions L, Stephansson O, Gemzell-Danielsson K. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. Hum Reprod. 2007 Oct;22(10):2647-52. Epub 2007 Jul 25.</citation>
    <PMID>17652452</PMID>
  </reference>
  <reference>
    <citation>Allen RH, Bartz D, Grimes DA, Hubacher D, O'Brien P. Interventions for pain with intrauterine device insertion. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007373. doi: 10.1002/14651858.CD007373.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;7:CD007373.</citation>
    <PMID>19588429</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 25, 2013</lastchanged_date>
  <firstreceived_date>August 3, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intrauterine device</keyword>
  <keyword>pain</keyword>
  <keyword>lidocaine gel</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
